Zobrazeno 1 - 10 of 52 pro vyhledávání: '"R. Henner"'
1
Akademický článek
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Autor: Fabrice Barlesi, Steven Kao, Philippe A Cassier, Hua Fang, Frances Fan, Kathryn Allaire, Shiming Ye, Debra T Chao, William R Henner, Joel S Hayflick, Michael A McDevitt
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background CD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associate
Externí odkaz: https://doaj.org/article/20dbdf5be81c4b86b9fc3af9b764237c
Zobrazit plný text záznamu
6
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Autor: William R Henner, Kathryn Allaire, Michael A. McDevitt, Hua Fang, Karen Kelly, Shiming Ye, Hedy L. Kindler, Frances Fan, Ki Y. Chung, Steven Kao, Lawrence Fong, Jason J. Luke, Anthony W. Tolcher, Christophe Le Tourneau, Debra Chao, Maulik Patel, Mustafa Khasraw, Antoine Hollebecque, Philippe A. Cassier, Fabrice Barlesi, Joel S Hayflick, Vivek Subbiah, Frank Tsai
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for Immunotherapy of Cancer
BackgroundCD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associated
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::222c39857b4470f6815b947401863ee2
https://jitc.bmj.com/content/9/2/e002015.full
Zobrazit plný text záznamu
7
Phase 1 first-in-human study of ABBV-184 monotherapy in adult patients with previously treated acute myeloid leukemia or non-small cell lung cancer
Autor: Maria Kovalenko, Toshio Shimizu, Junichiro Yuda, Kevin J. Freise, Pierre Peterlin, Yakir Moshe, Stacy Jaryno, Nashat Y. Gabrail, Esma Saada-Bouzid, Bruno Quesnel, William R Henner, Rachel S Leibman, Apurvasena Parikh, Donghui Huang, Abraham Avigdor, Mor Moskovitz, Edward B. Reilly
Publikováno v: Journal of Clinical Oncology. 39:TPS2674-TPS2674
TPS2674 Background: Survivin, a member of the inhibitor of apoptosis protein family, is an attractive therapeutic target in cancer, due to its broad expression in solid tumors and hematologic malignancies but limited expression in normal tissues. Ele
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::311713fa118f0bd0dce9a193e77e47f2
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2674
Zobrazit plný text záznamu
8
Abstract 5672: Pharmacodynamics and potential predictive biomarkers of ABBV-428, a first-in-class mesothelin (MSLN)-CD40 bispecific, in patients with advanced solid tumors
Autor: Tolga Turan, Shiming Ye, Anita Reddy, Andrew Woolley, Joel S Hayflick, William R Henner, Debra Chao, Kathryn Allaire, Hua Fang, Cyril Ramathal, Michael A. McDevitt, Frances Fan, Lawrence Fong, Kinjal Hew
Publikováno v: Cancer Research. 80:5672-5672
Background: ABBV-428 is a first-in-class bispecific antibody against CD40 and MSLN designed to stimulate CD40 for tumor-specific immune activation with limited systemic toxicity (Cancer Immunol Res 2019;7:1864). In phase I findings, ABBV-428 was well
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::816153de7f91d6d35fb0c6138a1bbf4f
https://doi.org/10.1158/1538-7445.am2020-5672
Zobrazit plný text záznamu
9
A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors
Autor: Talia Golan, Kathy D. Miller, Michael A. McDevitt, Anthony W. Tolcher, John D. Powderly, Daniel Dacosta, Patricia LoRusso, Martha Elizabeth Blaney, William R Henner
Publikováno v: Journal of Clinical Oncology. 38:TPS3147-TPS3147
TPS3147 Background: CD40 is a key costimulatory molecule for both the innate and adaptive immune systems that is essential for T-cell activation and proliferation. OX40 is a costimulatory molecule that is involved in enhancing nascent immune response
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::339df974a1db83cceabfa5618dd779f8
https://doi.org/10.1200/jco.2020.38.15_suppl.tps3147
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje